Could a common blood pressure pill protect the heart after valve replacement?
NCT ID NCT07735130
First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time
Summary
This trial tests whether angiotensin receptor blockers (ARBs), a type of blood pressure medication, can reduce the risk of death or heart failure in people who have had a transcatheter aortic valve replacement (TAVR) for severe aortic stenosis and still have a thickened heart muscle (left ventricular hypertrophy). About 630 participants will receive either an ARB or no ARB for up to 2 years. The goal is to see if blocking certain hormonal signals helps the heart recover after the valve is fixed.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an angiotensin receptor blocker (ARB) — candesartan, losartan, or valsartan
- What this could lead to
- If ARBs prove effective, this could become a standard treatment to reduce heart failure and death after TAVR in patients with left ventricular hypertrophy.
- What could go wrong
- This is an open-label trial, so results may be influenced by bias. ARBs can cause side effects like low blood pressure or kidney issues, and the trial's 2-year follow-up may not capture long-term effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEFT VENTRICULAR HYPERTROPHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Seoul National University Hospital
Seoul, Seoul, 03080, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A new heart valve without Open-Heart surgery: can it help High-Risk patients?
- Pacemaker signals may unmask a rare heart condition
- Can a single antiplatelet drug beat aspirin after heart valve replacement?
- Massive asian TAVR registry aims to unlock secrets of long-term valve success.
- Brain catcher: new device may prevent stroke during heart procedure
- Heart valve unit may cut brain fog after procedure, study hopes